Hjem › Paragangliom › Maryland
Kliniske studier for Paragangliom i Maryland
7 studier for Paragangliom søker deltakere på steder i Maryland.
Offisiell studietekst (engelsk)
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 1
Alder 18 til 120 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06479811Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108), Baltimore
- National Institutes of Health ( Site 0125), Bethesda
RekruttererFase 2
Alder 12 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT04924075Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 2
Alder 18 til 100 · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03206060Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 1/2
Alder 18 til 120 · Alle kjønn · Oppdatert 18. aug. 2026 · NCT06427798A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 1
Alder 18 til 120 · Alle kjønn · Oppdatert 15. jun. 2026 · NCT0604151618F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 2
Alder 18 til 120 · Alle kjønn · Oppdatert 19. mai 2026 · NCT06503146Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Johns Hopkins, Baltimore
RekruttererFase 1/2
Alder 18 til 90 · Alle kjønn · Oppdatert 14. mai 2026 · NCT05636618Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.